NSAID Label Revisions Likely Unavoidable Without New Trial Data – Jenkins
This article was originally published in The Tan Sheet
Executive Summary
NSAID marketers seeking substantial changes to revised labeling recently requested by FDA will likely need to submit new study data, according to the agency
You may also be interested in...
Requested OTC NSAID Labeling Includes Cardiac Risk, Front Panel Changes
Manufacturers of over-the-counter non-steroidal anti-inflammatory drugs should prominently identify their products as NSAIDs on packaging, according to an FDA request
Wyeth Says NSAID Risk Label May Confuse Consumers
Available evidence may not support a new FDA-requested NSAID cardiovascular risk warning for ibuprofen in an over-the-counter use context, according to Wyeth
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC